Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC15654 structure
    GC15654SBI-0206965
    CAS: 1884220-36-3
    纯度: >99.00%

    SBI-0206965,这种嘧啶衍生物是一种高选择性的激酶ULK1抑制剂,IC 50 值为108nM。

  • GC15658 structure
    GC15658R406(free base)
    CAS: 841290-80-0
    纯度: >99.50%

    A potent and selective Syk inhibitor

  • GC15659 structure
    GC15659GSK-923295
    CAS: 1088965-37-0
    纯度: >98.00%

    An inhibitor of CENP-E

  • GC15665 structure
    GC15665Quercetin dihydrate
    CAS: 6151-25-3

    槲皮素二水合物是一种天然类黄酮,是重组 SIRT1 的刺激剂和 PI3K 抑制剂,对 PI3K γ、PI3K δ 和 PI3K β 的 IC50 分别为 2.4 μM、3.0 μM 和 5.4 μM。

  • GC15670 structure
    GC15670Rabeprazole sodium
    CAS: 117976-90-6
    纯度: >99.00% / >98.00%

    A proton pump inhibitor

  • GC15680 structure
    GC15680Perifosine
    CAS: 157716-52-4
    纯度: >98.00%

    Perifosine 是 Akt 的抑制剂 。

  • GC15710 structure
    GC15710ML-354
    CAS: 89159-60-4

    A PAR4 antagonist

  • GC15739 structure
    GC15739CHIR-124
    CAS: 405168-58-3
    纯度: >98.00%

    A selective Chk1 inhibitor

  • GC15760 structure
    GC15760Ramipril
    CAS: 87333-19-5
    纯度: >98.00%

    A prodrug from of ramiprilat

  • GC15771 structure
    GC15771PYR-41
    CAS: 418805-02-4
    纯度: >98.00%

    PYR-41是一种不可逆的、细胞渗透性的泛素激活酶E1抑制剂,IC 50 值小于10μM,对E2和E3基本无作用。

  • GC15775 structure
    GC15775Metronidazole
    CAS: 443-48-1
    纯度: >98.00% / >99.50%

    An antibiotic

  • GC15779 structure
    GC15779Cabozantinib (XL184, BMS-907351)
    CAS: 849217-68-1
    纯度: >99.50%

    Cabozantinib (XL184,BMS-907351) 是一种新型 MET 和 VEGFR2 抑制剂,可同时抑制转移、血管生成和肿瘤生长。

  • GC15805 structure
    GC15805UMI-77
    CAS: 518303-20-3
    纯度: >97.50%

    A selective Mcl-1 inhibitor

  • GC15812 structure
    GC15812p-nitro-Pifithrin-α
    CAS: 389850-21-9
    纯度: >95.00%

    A cell-permeable inactivator of p53

  • GC15818 structure
    GC15818RAF265
    CAS: 927880-90-8
    纯度: >99.50%

    A B-Raf and VEGFR2 inhibitor

  • GC15857 structure
    GC15857Sodium butyrate
    CAS: 156-54-7
    纯度: >99.00%

    A short-chain fatty acid and HDAC inhibitor

  • GC15865 structure
    GC15865GRI 977143
    CAS: 325850-81-5
    纯度: >98.00%

    GRI 977143是一种针对溶血磷脂酸受体2(LPA 2 )的非脂类激动剂,EC 50 值为3.3μM。

  • GC15866 structure
    GC15866Capecitabine
    CAS: 154361-50-9
    纯度: >99.50% / >98.00%

    A prodrug of 5-fluorouracil

  • GC15870 structure
    GC15870AT7519
    CAS: 844442-38-2
    纯度: >99.50%

    A Cdk inhibitor

  • GC15880 structure
    GC15880Penicillic Acid
    CAS: 90-65-3
    纯度: >99.50% / >98.00%

    A mycotoxin that inhibits quorum sensing

  • GC15896 structure
    GC15896Z-Ile-Leu-aldehyde
    CAS: 161710-10-7
    纯度: >98.00%

    Z-Ile-Leu-aldehyde (Z-IL-CHO) 是一种有效的、竞争性的 γ-分泌酶和缺口肽醛抑制剂。

  • GC15904 structure
    GC15904PP242
    CAS: 1092351-67-1
    纯度: >98.50%

    Potent inhibitor of mTOR kinase in both mTORC1 and mTORC2

  • GC15946 structure
    GC15946ReACp53
    纯度: >99.00%

    ReACp53 可以抑制 p53 淀粉样蛋白的形成并挽救癌细胞系中的 p53 功能。

  • GC15980 structure
    GC15980WP1066
    CAS: 857064-38-1
    纯度: >99.50%

    WP1066是一种STAT3(信号转导和转录激活因子3)可逆的竞争性抑制剂,针对STAT3 Tyr705位点磷酸化的抑制IC 50 约为2.5μM,通常用于恶性肿瘤及炎症相关疾病的研究。